SenesTech Inc. reported Q2 2026 financial results with revenue increasing 23% year-over-year to $770K, driven primarily by its Evolve product. Despite a net loss of $1.83M, gross margins improved to 7
SenesTech reported narrower-than-expected losses and record revenue for Q2 2026, driven by strong e-commerce performance. Despite positive financial metrics, shares fell due to cash burn and lack of p
SenesTech reported Q2 2026 earnings with revenue up 23.2% to $770,000, surpassing analyst estimates. Diluted EPS narrowed to -$0.35, alongside notable insider stock purchases.
SenesTech reported Q2 2026 revenue up 23% to $770,000 driven by e-commerce, though net losses widened due to higher expenses. The company aims for profitability through sustained online growth and bet
SenesTech Inc reported record Q2 2026 revenue of $770,000, rising 56% sequentially, driven by e-commerce and agricultural B2B growth. Gross margins hit a record 73.6%.
SenesTech Inc will report Q2 2026 earnings on August 5, with estimated revenue of $0.6 million. GuruFocus forecasts a 74% downside despite analyst targets suggesting upside.
SenesTech Inc. will announce its Q2 2026 financial results after market close on August 5, 2026, with a concurrent conference call and webcast available via its Investor Relations website.
SenesTech reported record H1 2024 revenue driven by its Evolve rodent fertility control products, with Q2 revenue up 50% year-over-year. Management anticipates accelerated growth but notes additional
ChemBrief